Log in to save to my catalogue

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcin...

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2808215088

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

About this item

Full title

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

Journal title

Case reports in oncology, 2023, Vol.16 (1), p.273-278

Language

English

Formats

More information

Alternative Titles

Full title

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2808215088

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2808215088

Other Identifiers

ISSN

1662-6575

E-ISSN

1662-6575

DOI

10.1159/000530154

How to access this item